Table 4.
Median treatment duration, median TTP, and median PFS of everolimus by duration of previous VEGF-targeted treatment (efficacy population)
| Previous VEGF-targeted treatment | Treatment duration | TTP | PFS |
|---|---|---|---|
| Duration, months | Median, months (95% CI) | ||
| <3 (n = 54) vs. ≥3 (n = 203) | 6.6 (3–10) | 7.9 (4–11) | 7.1 (4–11) |
| 7.1 (5–9) | 7.5 (6–10) | 7.4 (6–9) | |
| p = .87 | p = .62 | ||
| <6 (n = 105) vs. ≥6 (n = 152) | 6.6 (4–9) | 6.8 (4–10) | 6.6 (4–10) |
| 7.5 (5–11) | 8.1 (7–10) | 7.8 (5–10) | |
| p = .86 | p = .70 | ||
| <9 (n = 133) vs. ≥9 (n = 124) | 6.6 (4–9) | 6.8 (4–10) | 6.6 (4–10) |
| 7.5 (5–11) | 8.2 (7–11) | 8.1 (7–10) | |
| p = .79 | p = .74 | ||
Abbreviations: CI, confidence interval; PFS, progression-free survival; TTP, time to progression; VEGF, vascular endothelial growth factor.
p value determined using log-rank test.